Drug intelligence / Profile preview

ANT-1401

Development stage: Unknown
Lead developer: Allergan
Modality: Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular, Intradermal

Overview

ANT-1401 is a biological drug developed by Anterios, Inc. It is a SNAP25 inhibitor, targeting the synaptosomal-associated protein 25 (SNAP25), and is classified as a botulinum neurotoxin type A product. Its primary mechanism of action involves inhibiting SNAP25, which plays a key role in neurotransmitter release at neuromuscular junctions. ANT-1401 has been investigated for cosmetic indications such as crow's feet and lateral canthal lines (facial wrinkles) in completed Phase 2 clinical trials[1][7]. The drug acts similarly to other botulinum toxin products by blocking acetylcholine release, resulting in temporary muscle relaxation.

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on ANT-1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT-1401.

Explore the full profile